Literature DB >> 12656618

Sanglifehrin-cyclophilin interaction: degradation work, synthetic macrocyclic analogues, X-ray crystal structure, and binding data.

Richard Sedrani1, Jörg Kallen, Luisa M Martin Cabrejas, Charles D Papageorgiou, Francesco Senia, Stefan Rohrbach, Dieter Wagner, Binh Thai, Anne-Marie Jutzi Eme, Julien France, Lukas Oberer, Grety Rihs, Gerhard Zenke, Jürgen Wagner.   

Abstract

Sanglifehrin A (SFA) is a novel immunosuppressive natural product isolated from Streptomyces sp. A92-308110. SFA has a very strong affinity for cyclophilin A (IC(50) = 6.9 +/- 0.9 nM) but is structurally different from cyclosporin A (CsA) and exerts its immunosuppressive activity via a novel mechanism. SFA has a complex molecular structure consisting of a 22-membered macrocycle, bearing in position 23 a nine-carbon tether terminated by a highly substituted spirobicyclic moiety. Selective oxidative cleavage of the C(26)=C(27) exocyclic double bond affords the spirolactam containing fragment 1 and macrolide 2. The affinity of 2 for cyclophilin (IC(50) = 29 +/- 2.1 nM) is essentially identical to SFA, which indicates that the interaction between SFA and cyclophilin A is mediated exclusively by the macrocyclic portion of the molecule. This observation was confirmed by the X-ray crystal structure resolved at 2.1 A of cyclophilin A complexed to macrolide 16, a close analogue of 2. The X-ray crystal structure showed that macrolide 16 binds to the same deep hydrophobic pocket of cyclophilin A as CsA. Additional valuable details of the structure-activity relationship were obtained by two different chemical approaches: (1) degradation work on macrolide 2 or (2) synthesis of a library of macrolide analogues using the ring-closing metathesis reaction as the key step. Altogether, it appears that the complex macrocyclic fragment of SFA is a highly optimized combination of multiple functionalities including an (E,E)-diene, a short polypropionate fragment, and an unusual tripeptide unit, which together provide an extremely strong affinity for cyclophilin A.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12656618     DOI: 10.1021/ja021327y

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  19 in total

1.  Synthesis and structure-activity relationship study of FD-891: importance of the side chain and C8-C9 epoxide for cytotoxic activity against cancer cells.

Authors:  Tomohiro Itagaki; Ayano Kawamata; Miho Takeuchi; Keisuke Hamada; Yoshiharu Iwabuchi; Tadashi Eguchi; Fumitaka Kudo; Takeo Usui; Naoki Kanoh
Journal:  J Antibiot (Tokyo)       Date:  2016-01-27       Impact factor: 2.649

2.  Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family.

Authors:  Matthew A Gregory; Michael Bobardt; Susan Obeid; Udayan Chatterji; Nigel J Coates; Teresa Foster; Philippe Gallay; Pieter Leyssen; Steven J Moss; Johan Neyts; Mohammad Nur-e-Alam; Jan Paeshuyse; Mahmood Piraee; Dipen Suthar; Tony Warneck; Ming-Qiang Zhang; Barrie Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

3.  Translation of DNA into a library of 13,000 synthetic small-molecule macrocycles suitable for in vitro selection.

Authors:  Brian N Tse; Thomas M Snyder; Yinghua Shen; David R Liu
Journal:  J Am Chem Soc       Date:  2008-10-29       Impact factor: 15.419

4.  Primary identification, biochemical characterization, and immunologic properties of the allergenic pollen cyclophilin cat R 1.

Authors:  Debajyoti Ghosh; Geoffrey A Mueller; Gabriele Schramm; Lori L Edwards; Arnd Petersen; Robert E London; Helmut Haas; Swati Gupta Bhattacharya
Journal:  J Biol Chem       Date:  2014-06-17       Impact factor: 5.157

5.  The overlap of small molecule and protein binding sites within families of protein structures.

Authors:  Fred P Davis; Andrej Sali
Journal:  PLoS Comput Biol       Date:  2010-02-05       Impact factor: 4.475

6.  The cyclophilin-binding agent Sanglifehrin A is a dendritic cell chemokine and migration inhibitor.

Authors:  Sabrina N Immecke; Nelli Baal; Jochen Wilhelm; Juliane Bechtel; Angela Knoche; Gregor Bein; Holger Hackstein
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

7.  Efficient trapping of HIV-1 envelope protein by hetero-oligomerization with an N-helix chimera.

Authors:  Wu Ou; Jonathan Silver
Journal:  Retrovirology       Date:  2005-08-10       Impact factor: 4.602

8.  Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection.

Authors:  Magnus Joakim Hansson; Steven James Moss; Michael Bobardt; Udayan Chatterji; Nigel Coates; Jose A Garcia-Rivera; Eskil Elmér; Steve Kendrew; Pieter Leyssen; Johan Neyts; Mohammad Nur-E-Alam; Tony Warneck; Barrie Wilkinson; Philippe Gallay; Matthew Alan Gregory
Journal:  Chem Biol       Date:  2015-01-22

Review 9.  Peptidylprolyl Isomerases as In Vivo Carriers for Drugs That Target Various Intracellular Entities.

Authors:  Andrzej Galat
Journal:  Biomolecules       Date:  2017-09-29

Review 10.  Medicinal chemistry strategies toward host targeting antiviral agents.

Authors:  Xingyue Ji; Zhuorong Li
Journal:  Med Res Rev       Date:  2020-02-14       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.